Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Issue 6 (16th April 2020)

• Record Type: Journal Article
• Authors: Lan, Xiabin; Bao, Hua; Ge, Xinyang; Cao, Jun; Fan, Xiaojun; Zhang, Qihong; Liu, Kaihua; Zhang, Xian; Tan, Zhuo; Zheng, Chuanming; Wang, Ao; Chen, Chao; Zhu, Xin; Wang, Jiafeng; Xu, Jiajie; Zhu, Xuhang; Wu, Xue; Wang, Xiaonan; Shao, Yang; Ge, Minghua
• Is Part Of: Cancer science. Volume 111:Issue 6(2020)
• Page Start: 2163
• Page End: 2173
• Publication Date: 2020-04-16
• Subjects: circulating tumor DNA -- distant metastasis -- mutation -- nomogram -- papillary thyroid carcinoma; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14389
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland, with a relatively high cure rate. Distant metastasis (DM) of PTC is uncommon, but when it occurs, it significantly decreases the survival of PTC patients. The molecular mechanisms of DM in PTC have not been systematically studied. We performed whole exome sequencing and GeneseeqPrime (425 genes) panel sequencing of the primary tumor, plasma and matched white blood cell samples from 20 PTC with DM and 46 PTC without DM. We identified somatic mutations, gene fusions and copy number alterations and analyzed their relationships with DM of PTC. BRAF‐V600E was identified in 73% of PTC, followed by RET fusions (14%) in a mutually exclusive manner ( P < 0.0001). We found that gene fusions ( RET, ALK or NTRK1 ) ( P < 0.01) and chromosome 22q loss ( P < 0.01) were independently associated with DM in both univariate and multivariate analyses. A nomogram model consisting of chromosome 22q loss, gene fusions and three clinical variables was built for predicting DM in PTC (C‐index = 0.89). The plasma circulating tumor DNA (ctDNA) detection rate in PTC was only 38.9%; however, it was significantly associated with the metastatic status ( P = 0.04), tumor size ( P = 0.001) and invasiveness ( P = 0.01). In conclusion, gene fusions and chromosome 22q loss were independently associated with DM in PTC and could serve as molecular biomarkers for predicting DM. The ctDNA detection rate was low in non–DM PTC but significantly higher in PTC with DM. Abstract : The study identified gene fusion and somatic copy number alterations, particularly chromosome 22q loss, to be risk factors for distance metastasis (DM) of PTC and provided a convenient tool for the prediction of PTC DM.